Craft
Aravive

Aravive

Revenue

$7.4 M

FY, 2021

Market Capitalization

$19.3 M

2022-09-21

Aravive Summary

Company summary

Overview
Aravive is a clinical-stage biotechnology company developing therapies for solid tumors and hematologic malignancies. It develops AVB-S6-500, a GAS6 binding protein and AXL decoy receptor for the treatment of ovarian cancer, renal cell carcinoma, acute myeloid leukemia, triple-negative breast cancer, and pancreatic cancer. The company was formed as a result of a merger between Versartis and Aravive Biologics.
Type
Public
Founded
2008
HQ
Houston, TX, US | view all locations
Website
https://www.aravive.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Gail McIntyre

    Gail McIntyre, Chief Executive Officer, Director

  • Vinay Shah

    Vinay Shah, Chief Financial Officer

  • Fred Eshelman

    Fred Eshelman, Chairman of the Board

    • Amato Giaccia

      Amato Giaccia, Director

      LocationsView all

      1 location detected

      • Houston, TX HQ

        United States

        3730 Kirby Dr #1200

      Aravive Financials

      Summary financials

      Revenue (Q2, 2022)
      $1.6M
      Net income (Q2, 2022)
      ($18.5M)
      Cash (Q2, 2022)
      $46.8M
      EBIT (Q2, 2022)
      ($19.4M)
      Enterprise value
      ($22.3M)

      Footer menu